Eric Tai1, Lori A Pollack, Julie Townsend, Jun Li, C Brooke Steele, Lisa C Richardson. 1. Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 4770 Buford Hwy NE, Atlanta, GA 30341, USA. cvn5@cdc.gov
Abstract
OBJECTIVE: To examine differences in non-Hodgkin lymphoma (NHL) survival between young adults and children/adolescents. DESIGN: Survival analysis using 13 Surveillance, Epidemiology, and End Results registries. SETTING: Cancer survival information from population-based cancer registries from 1992 through 2001. PARTICIPANTS: A total of 2442 cases of NHL among children/adolescents (aged 0-19 years) and young adults (aged 20-29 years). MAIN EXPOSURE: Differences in NHL survival between young adults and children. MAIN OUTCOME MEASURES: Comparison of 5-year survival by constructing Kaplan-Meier survival curves and modeling 5-year survival with multivariate Cox proportional hazards. RESULTS: Young adults were more likely to die compared with children/adolescents (hazard ratio = 2.06; 95% confidence interval, 1.65-2.56) even after accounting for NHL subtype and stage at diagnosis. Persons diagnosed with stage III disease (hazard ratio = 1.71; 95% confidence interval, 1.20-2.46) and stage IV disease (hazard ratio = 3.19; 95% confidence interval, 2.47-4.13) were more likely to die compared with persons diagnosed with stage I disease. CONCLUSIONS: Being a young adult at diagnosis and having a higher stage of disease at diagnosis were associated with higher risk of death from NHL. Increasing survival with NHL is dependent on receiving appropriate cancer therapy. Therefore, efforts to address survival should include improving enrollment in clinical trials as well as increasing access to care.
OBJECTIVE: To examine differences in non-Hodgkin lymphoma (NHL) survival between young adults and children/adolescents. DESIGN: Survival analysis using 13 Surveillance, Epidemiology, and End Results registries. SETTING:Cancer survival information from population-based cancer registries from 1992 through 2001. PARTICIPANTS: A total of 2442 cases of NHL among children/adolescents (aged 0-19 years) and young adults (aged 20-29 years). MAIN EXPOSURE: Differences in NHL survival between young adults and children. MAIN OUTCOME MEASURES: Comparison of 5-year survival by constructing Kaplan-Meier survival curves and modeling 5-year survival with multivariate Cox proportional hazards. RESULTS: Young adults were more likely to die compared with children/adolescents (hazard ratio = 2.06; 95% confidence interval, 1.65-2.56) even after accounting for NHL subtype and stage at diagnosis. Persons diagnosed with stage III disease (hazard ratio = 1.71; 95% confidence interval, 1.20-2.46) and stage IV disease (hazard ratio = 3.19; 95% confidence interval, 2.47-4.13) were more likely to die compared with persons diagnosed with stage I disease. CONCLUSIONS: Being a young adult at diagnosis and having a higher stage of disease at diagnosis were associated with higher risk of death from NHL. Increasing survival with NHL is dependent on receiving appropriate cancer therapy. Therefore, efforts to address survival should include improving enrollment in clinical trials as well as increasing access to care.
Authors: J M Snaman; A C Talleur; J Lu; D R Levine; E C Kaye; A Sykes; Z Lu; B M Triplett; J N Baker Journal: Bone Marrow Transplant Date: 2017-11-13 Impact factor: 5.483
Authors: Dava Szalda; Marilyn M Schapira; Linda A Jacobs; Steven C Palmer; Carolyn Vachani; James Metz; Christine Hill-Kayser Journal: J Adolesc Young Adult Oncol Date: 2018-03-23 Impact factor: 2.223
Authors: Joelle P Straehla; Krysta S Barton; Joyce P Yi-Frazier; Claire Wharton; Kevin Scott Baker; Kira Bona; Joanne Wolfe; Abby R Rosenberg Journal: J Palliat Med Date: 2017-01-04 Impact factor: 2.947
Authors: Tyler G Ketterl; Karen L Syrjala; Jacqueline Casillas; Linda A Jacobs; Steven C Palmer; Mary S McCabe; Patricia A Ganz; Linda Overholser; Ann Partridge; Emily Jo Rajotte; Abby R Rosenberg; Betsy Risendal; Donald L Rosenstein; Kevin Scott Baker Journal: Cancer Date: 2019-02-01 Impact factor: 6.860
Authors: C Casulo; B Day; K L Dawson; X Zhou; C R Flowers; C M Farber; J D Hainsworth; J R Cerhan; B K Link; A D Zelenetz; J W Friedberg Journal: Ann Oncol Date: 2015-09-11 Impact factor: 32.976
Authors: Terri Patricia McVeigh; Raghav Sundar; Nikolaos Diamantis; Stan B Kaye; Udai Banerji; Juanita S Lopez; Johann de Bono; Winette T A van der Graaf; Angela J George Journal: Eur J Cancer Date: 2018-03-31 Impact factor: 9.162